Corvus Pharmaceuticals Ownership
| CRVS Stock | USD 9.09 0.33 3.50% |
Shares in Circulation | First Issued 2016-03-31 | Previous Quarter 60 M | Current Value 67 M | Avarage Shares Outstanding 34.2 M | Quarterly Volatility 14 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Corvus |
Corvus Stock Ownership Analysis
About 44.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 0.99. Corvus Pharmaceuticals had not issued any dividends in recent years. Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. The company was incorporated in 2014 and is based in Burlingame, California. Corvus Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 28 people. For more info on Corvus Pharmaceuticals please contact the company at 650 900 4520 or go to https://www.corvuspharma.com.Besides selling stocks to institutional investors, Corvus Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Corvus Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Corvus Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Corvus Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Corvus Pharmaceuticals Insider Trades History
About 4.0% of Corvus Pharmaceuticals are currently held by insiders. Unlike Corvus Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Corvus Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Corvus Pharmaceuticals' insider trades
Corvus Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Corvus Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Corvus Pharmaceuticals backward and forwards among themselves. Corvus Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Corvus Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Schonfeld Strategic Advisors Llc | 2024-09-30 | 331.4 K | Millennium Management Llc | 2024-06-30 | 204.6 K | Bridgeway Capital Management, Llc | 2024-09-30 | 127.3 K | Citigroup Inc | 2024-09-30 | 122.9 K | State Street Corp | 2024-06-30 | 120.3 K | Towerview Llc | 2024-09-30 | 117.5 K | Two Sigma Advisers, Llc | 2024-06-30 | 113.4 K | Northern Trust Corp | 2024-09-30 | 105.5 K | Citadel Advisors Llc | 2024-09-30 | 97.1 K | Orbimed Advisors, Llc | 2024-06-30 | 6.9 M | Point72 Asset Management, L.p. | 2024-09-30 | 5.6 M |
Corvus Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Corvus Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Corvus Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Corvus Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Corvus Pharmaceuticals Outstanding Bonds
Corvus Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Corvus Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Corvus bonds can be classified according to their maturity, which is the date when Corvus Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Corvus Pharmaceuticals Corporate Filings
8K | 12th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 1st of August 2024 An amended filing to the original Schedule 13G | ViewVerify |
F4 | 17th of June 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 9th of May 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Corvus Stock Analysis
When running Corvus Pharmaceuticals' price analysis, check to measure Corvus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corvus Pharmaceuticals is operating at the current time. Most of Corvus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corvus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corvus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corvus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.